Protease Inhibitors

• 

  Subject Areas on Research

  • 2-O, 3-O-desulfated heparin inhibits neutrophil elastase-induced HMGB-1 secretion and airway inflammation. 
  • A three-dimensional model of a unique proteinase inhibitor: alpha 2-macroglobulin. 
  • A unique pathway for the plasma elimination of alpha 2-antiplasmin-protease complexes in mice. 
  • ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein. 
  • Adherence counseling practices of generalist and specialist physicians caring for people living with HIV/AIDS in North Carolina. 
  • Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. 
  • Allograft airway fibrosis in the pulmonary milieu: a disorder of tissue remodeling. 
  • Alpha-macroglobulin from Limulus polyphemus exhibits proteinase inhibitory activity and participates in a hemolytic system. 
  • Altered pigment epithelium-derived factor and vascular endothelial growth factor levels in lymphangioma pathogenesis and clinical recurrence. 
  • Anti-epidermal-cell-surface pemphigus antibody detaches viable epidermal cells from culture plates by activation of proteinase. 
  • Antibody-induced release of cellular proteinases: loss of adhesion of human melanoma cells after binding of anti-melanoma antibody. 
  • Antiretroviral therapy: evaluating the new era in HIV treatment. 
  • Association of race and gender with use of antiretroviral therapy among HIV-infected individuals in the Southeastern United States. 
  • Bombesin-like peptides and receptors in normal fetal baboon lung: roles in lung growth and maturation. 
  • CD10/neutral endopeptidase inhibition augments pulmonary neuroendocrine cell hyperplasia in hamsters treated with diethylnitrosamine and hyperoxia. 
  • Calcineurin mediates pancreatic growth in protease inhibitor-treated mice. 
  • Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. 
  • Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection. 
  • Challenges for providing effective hemostasis in surgery and trauma. 
  • Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. 
  • Characteristics of the chemotactic activity of heparin cofactor II proteolysis products. 
  • Characterization of a chemotactic and cytotoxic proteinase from human skin. 
  • Chlamydia protease-like activity factor (CPAF): characterization of proteolysis activity in vitro and development of a nanomolar affinity CPAF zymogen-derived inhibitor. 
  • Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. 
  • Coagulopathy in COVID-19. 
  • Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. 
  • Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay. 
  • Development of a high-throughput screening assay for inhibitors of small ubiquitin-like modifier proteases. 
  • Difluoroethylamines as an amide isostere in inhibitors of cathepsin K. 
  • Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. 
  • Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. 
  • Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome. 
  • Effect of cyclooxygenase inhibitors and protease inhibitors on phorbol-induced stimulation of oxygen consumption and superoxide production by rat pulmonary macrophages. 
  • Effect of inhibitors of proteolytic enzymes on the growth of normal and polyoma transformed BHK cells. 
  • Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. 
  • Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. 
  • Emergence of factor IXa as a target for pharmacologic inhibition: editors page. 
  • Endogenous proteinases modulate the function of the beta-adrenergic receptor-adenylate cyclase system. 
  • Evidence for involvement of metalloendoproteases in a step in sea urchin gamete fusion. 
  • Evidence for polymorphonuclear-leucocyte-derived proteinases in arthritic cartilage. 
  • Evidence that non-caspase proteases are required for chromatin degradation during apoptosis. 
  • Fragment-Based De Novo Design Reveals a Small-Molecule Inhibitor of Helicobacter Pylori HtrA. 
  • Functional selection of protease inhibitory antibodies. 
  • Gut peptides in the treatment of diabetes mellitus. 
  • Hemorrhage in lesions caused by cowpox virus is induced by a viral protein that is related to plasma protein inhibitors of serine proteases. 
  • Identification of monomeric alpha-macroglobulin proteinase inhibitors in birds, reptiles, amphibians and mammals, and purification and characterization of a monomeric alpha-macroglobulin proteinase inhibitor from the American bullfrog Rana catesbeiana. 
  • Impact of Non-Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective. 
  • In vivo catabolism of alpha 1-antichymotrypsin is mediated by the Serpin receptor which binds alpha 1-proteinase inhibitor, antithrombin III and heparin cofactor II. 
  • In vivo catabolism of heparin cofactor II and its complex with thrombin: evidence for a common receptor-mediated clearance pathway for three serine proteinase inhibitors. 
  • In vivo metabolism of inter-alpha-trypsin inhibitor and its proteinase complexes: evidence for proteinase transfer to alpha 2-macroglobulin and alpha 1-proteinase inhibitor. 
  • Independent analysis of bait region cleavage dependent and thiolester bond cleavage dependent conformational changes by cross-linking of alpha 2-macroglobulin with cis-dichlorodiammineplatinum(II) and dithiobis(succinimidyl propionate). 
  • Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy. 
  • Inhibition of 125I-chemotactic peptide uptake by protease inhibitors. 
  • Inhibition of matrix metalloproteinases enhances in vitro repair of the meniscus. 
  • Inhibitors of metalloendoprotease activity prevent K+-stimulated neurotransmitter release from the retina of Xenopus laevis. 
  • Inhibitory effect of b-AP15 on the 20S proteasome. 
  • Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. 
  • Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. 
  • Is renin a factor in the etiology of essential hypertension? 
  • Isolation of the JMH antigen on a novel phosphatidylinositol-linked human membrane protein. 
  • L-DOPA is an endogenous ligand for OA1. 
  • L-selectin shedding does not regulate human neutrophil attachment, rolling, or transmigration across human vascular endothelium in vitro. 
  • Ligand binding, conformational change and plasma elimination of human, mouse and rat alpha-macroglobulin proteinase inhibitors. 
  • Limited proteolysis of the alpha-macroglobulin rat alpha 1-inhibitor-3. Implications for a domain structure. 
  • Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy. 
  • Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. 
  • Lysosomes and the skin. 
  • Matrix metalloprotease regulation of neuropathic pain. 
  • Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis. 
  • Mechanism of hypochlorite-mediated inactivation of proteinase inhibition by alpha 2-macroglobulin. 
  • Methionine sulfoxide and the oxidative regulation of plasma proteinase inhibitors. 
  • Model of alpha 2-macroglobulin structure and function. 
  • Myoepithelial-specific CD44 shedding contributes to the anti-invasive and antiangiogenic phenotype of myoepithelial cells. 
  • Neuropeptides and capsaicin stimulate the release of inflammatory cytokines in a human bronchial epithelial cell line. 
  • New member of the trefoil factor family of proteins is an alpha-macroglobulin protease inhibitor. 
  • Non-peptidic, non-prenylic inhibitors of the prenyl protein-specific protease Rce1. 
  • Novel therapies for pancreatic adenocarcinoma. 
  • Pancreatic growth: interaction of exogenous cholecystokinin, a protease inhibitor, and a cholecystokinin receptor antagonist in mice. 
  • Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. 
  • Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. 
  • Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. 
  • Photoaffinity labelling of mammalian beta-adrenergic receptors: metal-dependent proteolysis explains apparent heterogeneity. 
  • Polymorphonuclear leukocytes: possible mechanism of accumulation in psoriasis. 
  • Presence of the protein-glycosaminoglycan-protein covalent cross-link in the inter-alpha-inhibitor-related proteinase inhibitor heavy chain 2/bikunin. 
  • Production of chemotactic peptides by neutrophil degradation of heparin cofactor II. 
  • Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. 
  • Protease inhibitors implicate metalloendoprotease in synaptic transmission at the mammalian neuromuscular junction. 
  • Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation. 
  • Proteasome regulators: activators and inhibitors. 
  • Proteinase binding and inhibition by the monomeric alpha-macroglobulin rat alpha 1-inhibitor-3. 
  • Pseudomonas aeruginosa Leucine Aminopeptidase Influences Early Biofilm Composition and Structure via Vesicle-Associated Antibiofilm Activity. 
  • Pseudomonas aeruginosa elastase degrades surfactant proteins A and D. 
  • Purification and characterization of an alpha-macroglobulin proteinase inhibitor from the mollusc Octopus vulgaris. 
  • Purification and partial characterization of a thiol proteinase from the thermophilic fungus Humicola lanuginosa. 
  • Quantitative high-throughput screening identifies cytoprotective molecules that enhance SUMO conjugation via the inhibition of SUMO-specific protease (SENP)2. 
  • Rat myoblast fusion requires metalloendoprotease activity. 
  • Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. 
  • Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors. 
  • Regulation of factor Xa in vitro in human and mouse plasma and in vivo in mouse. Role of the endothelium and plasma proteinase inhibitors. 
  • Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. 
  • Requirement for metalloendoprotease in exocytosis: evidence in mast cells and adrenal chromaffin cells. 
  • Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. 
  • Selectivity and stereospecificity of the reactions of dichlorodiammineplatinum(II) with three purified plasma proteins. 
  • Specific blockers of myoblast fusion inhibit a soluble and not the membrane-associated metalloendoprotease in myoblasts. 
  • Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. 
  • Strategies of antiretroviral therapy in adults. 
  • Structural and functional analysis of the spontaneous re-formation of the thiol ester bond in human alpha 2-macroglobulin, rat alpha 1-inhibitor-3 and chemically modified derivatives. 
  • Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. 
  • Synthesis and proteasome inhibition of glycyrrhetinic acid derivatives. 
  • Synthesis and proteasome inhibition of lithocholic acid derivatives. 
  • Telaprevir for the treatment of chronic hepatitis C infection. 
  • The Chlamydia protease CPAF regulates host and bacterial proteins to maintain pathogen vacuole integrity and promote virulence. 
  • The biochemistry of haemostasis. 
  • The effect of phosphatidylserine on the inhibition of human factor Xa by the plasma proteinase inhibitors. 
  • The effect of zinc and other divalent cations on the structure and function of human alpha 2-macroglobulin. 
  • The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. 
  • The glucocorticoid receptor interacting protein 1 (GRIP1) localizes in discrete nuclear foci that associate with ND10 bodies and are enriched in components of the 26S proteasome. 
  • The potential role of alpha 2-macroglobulin in the control of cysteine proteinases (gingipains) from Porphyromonas gingivalis. 
  • The protease inhibitor era: an opportunity to improve the quality of care. 
  • The role of endothelium in factor Xa regulation: the effect of plasma proteinase inhibitors and hirudin. 
  • The role of inter-alpha-trypsin inhibitor and other proteinase inhibitors in the plasma clearance of neutrophil elastase and plasmin. 
  • The soluble metalloendoprotease required in myoblast fusion remains intracellular. 
  • Transactivation of the epidermal growth factor receptor by angiotensin II in glomerular podocytes. 
  • Treating HCV Infection: It Doesn't Get Much Better Than This. 
  • Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. 
  • Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches. 
  • Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure. 
  • Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. 
  • alpha 1-Microglobulin destroys the proteinase inhibitory activity of alpha 1-inhibitor-3 by complex formation. 
• 

  Keywords of People

  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • Hoffman, Maureane, Professor of Pathology, Integrative Immunobiology
  • Yancy Jr., William Samuel, Professor of Medicine, Medicine, General Internal Medicine